QIAGEN Bioinformatics and NGS Solutions Enable Genomic Breakthroughs

HILDEN, Germany and GERMANTOWN, Maryland, October 12, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its Sample to Insight solutions, from next-generation sequencing (NGS) technologies to bioinformatics solutions for research and clinical testing, figure prominently in independent studies presented this week at the American Society of Human Genetics (ASHG) annual meeting in Orlando, Florida. The ASHG 2017 conference, from October 17-21, attracts leaders in research and clinical applications from around the world, offering scientific sessions on new technologies in molecular biology and discoveries regarding genomic influences on disease.

Click here for the full press release

https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-12-ASHG-Abstracts?sc_lang=en

Contacts:

QIAGEN
Investor Relations
John Gilardi
e-mail: [email protected]
+49-2103-29-11711

Public Relations
Dr. Thomas Theuringer
e-mail: [email protected]
+49-2103-29-11826

SOURCE Qiagen N.V.